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Presence of an anti-viral factor in peritoneal dialysis effluent. Viral
peritonitis is an exceptionally rare occurrence in peritoneal dialysis. In
fact, up to now, only one case report has been documented in the
literature. In a prospective study, peritoneal dialysis effluent (PDE) was
specifically cultured for the following viruses: the herpes group of
viruses, including herpes simplex types I (HSV) and II, cytomegalovi-
rus (CMV) and varicella-zoster (V-Z), and the enteroviruses group
including coxsackie B-S (Cox B), echo, enterovirus and polio, Cultures
were performed under both basal conditions and in the presence of
peritonitis. No viral growth was demonstrated. The possible existence
of an anti-viral factor in the PDE was therefore raised. In order to
investigate this hypothesis, the PDE of 16 patients undergoing intermit-
tent peritoneal dialysis and of 24 patients on continuous ambulatory
peritoneal dialysis were examined for anti-viral activity. The method
used was analogous to that employed for testing the anti-viral effect of
interferon (IFN). The inhibition of the cytopathic effect (CPE) of
various viruses was examined in the following tissue cultures: Vero
cells (a line of monkey kidney cells) incubated with HSV, vesicular
stomatitis virus (VSV) and Cox B; human kidney cells incubated with
parainfluenza 3 (Para-3); human foreskin fibroblasts incubated with
CMV, HSV and VSV and L-929 (a line of mouse cells) incubated with
VSV. As control, unused Dianeal (Travenol, Ashdod, Israel) 1.5 and
4.25 g/dl, normal saline and 5 g/dl dextrose solutions were tested under
the same conditions using VSV on Vero. The PDE was also examined
for the presence of specific anti-viral antibodies by microneutralization
and ELISA tests. The presence of human IFN (/3 and y) was evaluated
by radioimmunoassay using anti IFN monoclonal antibodies. Human
IFN a was tested by a bioassay using MBDK cells with VSV. PDE from
both patients on intermittent peritoneal dialysis and continuous ambu-
latory peritoneal dialysis inhibited the cytopathic activity of all the
viruses tested in the various tissue cultures, except for the mouse line
of cells. No such inhibition was seen with the control solutions. Only
antibodies to HSV were detected in the PDE and their titer did not
correlate with the inhibition of cytopathic effect. Human IFN a, /3 and
were not detected. These studies suggest that PDE contains an
anti-viral factor which is not a known IFN or an anti-viral antibody.
This factor is active against both RNA and DNA viruses in both human
and monkey cell cultures.
Peritoneal dialysis (PD) is an established mode of treatment
for end-stage renal disease [1]. Peritonitis continues to be one of
the major complications of this form of treatment [2—6]. Al-
though both bacterial and fungal peritonitis have been well
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documented [2, 4, 6—8], there is only one isolated case report of
viral peritonitis [9].
It is accepted, however, that up to 20% of all episodes of
peritonitis are sterile or culture-negative [6]. Whether this group
harbors viral agents within it which are not detected by the
conventional culture methods used [10, 11] is a matter of
conjecture. In a prospective study, the PDE obtained from
patients treated by PD, was specifically cultured for the herpes
and enterovirus groups of viruses under both basal conditions
and in the presence of peritonitis. All the PDE cultured yielded
no virus growth.
End-stage renal disease can be viewed as an acquired immu-
nodeficiency state. Uremic patients are prone to infections and
to the development of malignancies [12]. The absence of viral
peritonitis is therefore all the more striking. In view of this, the
possible existence of an anti-viral factor (AVF) in the PDE was
raised. Among the naturally occurring AVF's in man are human
interferon (IFN) [13, 14] and specific anti-viral antibodies. The
present work was designed to ascertain (i) whether indeed PDE
contains an AVF, (ii) whether the anti-viral effect is mediated
by anti-viral antibodies, and (iii) whether this AVF is related to
the IFN group of compounds.
Methods
Patient population
Peritoneal dialysis effluent from 16 patients treated by inter-
mittent peritoneal dialysis (PDE-I) and from 24 patients on
continuous ambulatory peritoneal dialysis (PDE-C) were exam-
ined in the present study. There were 24 males and 18 females;
mean age was 59.6 16.4 years, mean duration of time on
dialysis 17.8 13 months. At the time of the study all the
patients were deemed to be adequately dialyzed by clinical,
biochemical and electro-encephalographic data. Intermittent
PD was manually performed for a total of 36 hours per week (12
hours thrice weekly), using 1.5 and 4.25 g/dl Dianeal solutions
(Travenol, Ashdod, Israel, code numbers AMB-5206 and AMB-
5236, respectively). All solutions were preheated to 37°C. Dwell
time was 40 minutes. PDE was obtained by irrigating the
peritoneal cavity with 50 ml of normal saline prior to the
beginning of a regular intermittent PD session. After a 30
minute dwell, of these 50 ml, approximately 30 to 50 ml were
drained.
Patients treated by continuous ambulatory PD (CAPD) per-
formed four exchanges daily. PDE from these patients was
obtained by draining 50 ml from the overnight dwell bag
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(usually after a 6 to 8 hour dwell time). All PDE samples were
stored at —70°C until tested.
Due to the different methods of collection, PDE-I was con-
centrated while PDE-C was of necessity diluted in at least two
liters of dialy sate. PDE-C was examined both in its dilute form
and after lyophilization (achieving a concentration x 30).
Tissue cultures (TC) and viruses
Vero cells/human kidney cells. Each of these tissue cultures
contained a suspension of either monkey kidney cells (Vero)
[15] or human kidney cells (Hu-K) numbering 3 x iO cells/mi in
M-199 media and 5% calf serum added onto semimicroplates
(Nunc catalogue number 1-43982). One ml of the suspension
was added to each well of the plates (6 rows of 4 wells). The
plate was then incubated for 24 hours in an atmosphere con-
taining room air and 5% carbon dioxide (CO2).
Human foreskin fibroblasts (FS-11) and Wish amniotic cells.
A suspension of human foreskin fibroblasts (FS-l 1) [16] and
Wish cells [17] (Weizmann Institute, Rehovot, Israel) contain-
ing 3 to 4 x io cells/ml of each cell type were cultured in
Dulbecco minimal essential medium (DMEM) with 10% fetal
calf serum. TC plates were prepared as above.
L929. This TC of mice fibroblasts [18] (Weizmann Institute,
Rehovot, Israel) was prepared as for FS-li.
Viruses. The following viruses were used in the experiments:
1. Vesicular stomatitis virus (VSV)-India na strain
2. Cytomegalovirus (CMV)AD-l69 strain
3. Herpes simplex virus (HSV-I)
4. Coxsackie B-S virus (Cox B)
5. Parainfluenza-3 virus (Para-3)
The strain of HSV-I was isolated from a child with herpes
labialis and typed using monofluokit HSV of the Institut Pas-
teur. The Cox B strain (Coxsackie B-5) was obtained from the
Virology Laboratory, Chaim Sheba Medical Center, Tel-Hash-
omer, Israel. Intraconjuctival and intradermal inoculation in
two-day-old suckling mice resulted in the appearance of a
spastic paralysis and tremor after two to three days. Final
identification was accomplished by a neutralization test using a
specific anti-Cox B-5 serum prepared in the Department of
Human Microbiology, Sackler School of Medicine, Tel-Aviv
University.
Para-3 was also obtained from the Virology Laboratory,
Chaim Sheba Medical Center. It was further identified in the
Department of Human Microbiology, Tel-Aviv University, by
observing syncytial formation in Hu-K and by the hemadsorp-
tion test using guinea pig red blood cells in chick and Vero cells.
The above viruses were titrated in the corresponding TC and
virus dilutions of 10, 100 and 1000 tissue culture infective dose
50 (TCID50) [19] were used in each plate (Fig. 1).
Attempts to isolate virus from PDE
One hundred and twenty-nine PDE samples were cultured in
Vero cell and FS-1 1 in an attempt to isolate viruses. Of these
129 samples, 18 were obtained under conditions considered as
clinical peritonitis. Each sample of PDE was inoculated onto
Vero and FS-1 1 (0.5 ml to each well). TC were inspected daily
for the appearance of CPE. After seven days, the negative TC
(showing no CPE) were passaged to new TC plates and re-
examined at the end of a further seven days. TC plates were
actually incubated for 21 days in order to exclude the presence
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Fig. 1. Representative tissue culture plate showing the inhibition of the
cytopathic effect (CPE) of virus by various peritoneal dialysis effluents(PDE 1-5). This particular plate is that of VSV on Vero. Clear wells
indicate lysis of cells. Shaded wells are indicative of lack of CPE.
of either CMV or V-Z virus. Lack of CPE at the termination of
this two week period was then considered as negative for virus
growth.
Tests for the presence of anti-viral activity (AVA) in PDE
One hundred and seventy-six samples of PDE from the
patient population studied were examined. TC plates were
prepared one day prior to the testing. Each sample of PDE was
added to each of the four wells in the five horizontal rows.
Immediately following the addition of PDE, 0.5 ml of virus, in
dilutions —3, —4, —5 (corresponding to: 1000, 100 and 10
TCID50) was added to each well of the first three vertical rows.
The fourth vertical row contained media and PDE and served as
the PDE control. The sixth horizontal row contained 0.5 ml of
media in addition to the virus and served as virus control (Fig.
1). Plates utilizing Para-3 as virus were examined only in the
one virus dilution, namely —3, but in different concentrations of
PDE ranging from 1/4 to 1/64. The plates were incubated in
room air and 5% CO2 until the appearance of CPE in the virus
control wells (ito 2 days for VSV, HSV, Cox B and Para-3 and
5 to 7 days for CMV). When the CPE in the virus control
reached a maximum designated as +4 [20], the degree of CPE
obtained by the different PDE samples was determined using an
inverted microscope. CPE thus ranged from a maximal +4
downwards to +3, +2, +1, + and nil. On the other hand, the
inhibition of CPE was scored according to an arbitrary scale;
0.125, 0.25, 0.5, 1, 2, and 3 correspond respectively to the
above CPE determinations. An inhibitory CPE value of 0.125
therefore signified an absence of inhibition whereas a value of 3
represented maximal inhibition of CPE. This inhibitory effect of
CPE was taken as a measure of the anti-viral activity. The
plates were then fixed with methanol and stained with Giemsa.
After staining, the plates were once again evaluated for the
presence or absence of CPE using the scoring system outlined
above. The score of each virus dilution was then compared to
that of virus control.
In addition, using Para-3 on Vero (CPE of which is mani-
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fested by distinct plaques) the number of plaques was counted.
The number obtained by virus control was taken as 100% CPE.
Inhibition of CPE was measured as a percentage of the CPE
shown by virus control.
The PDE samples were examined for AVA using different
viruses and tissue cultures as previously detailed. PDE-C were
tested in both the dilute form and after lyophilization (achieving
a concentration x 30). Using the same experimental procedure,
the following solutions were also tested for AVA: Dianeal 1.5
gldl and 4.25 g/dl (Travenol, Ashdod, Israel), saline 0.9 g/dl and
dextrose 5 g/dl.
Minimal inhibitory concentration (MIC)
In order to determine the MIC of the AVF, five samples of
PDE-I were examined for their AVA in dilutions ranging from
1/2 to 1/64. The AVA of each sample was recorded against HSV
(dilution —4), VSV (dilution —5) and Cox B (dilution —3) on
Vero cells.
Anti-viral activity of PDE versus standard IFN
Ten samples of PDE-I (0.5 ml) were incubated for 24 hours
onto FS-1 1 and human Wish amniotic cells. Following this
24-hour incubation period, 100 TCID5Q of VSV (the challenge
virus) were added to each well. The plates were then re-
incubated for an additional 24 to 48 hours after which the
inhibition of CPE of each PDE sample was determined. Stan-
dard human IFN f3 [21], fibroblast IFN G023-902-527, and IFN
y [22], leucocyte immune IFN Gg23-901-530, were used as
controls.
A second set of experiments, similar to the above, was
performed except for the fact that following the 24-hour incu-
bation period, the plates were rinsed free of PDE with phos-
phate buffered solution (PBS) before the addition of VSV.
Assays for human JFN
Five samples of PDE-I were tested for the presence of human
IFN. Human IFN a was searched for by using a bioassay of
MDBK cells with VSV [23] (Institute of Biology, Nes-Ziona,
Israel). The presence of IFN /3 and y was evaluated by
radioimmunoassay (RIA) using monoclonal antibodies directed
against IFN /3 and y (Interyeda, Rehovot, Israel) [24].
Characterization of anti-viral activity
The AVA of four samples of PDE-I was examined on Vero
plates with VSV (dilutions —4) varying the sequence of incu-
bation as follows: (i) PDE was incubated onto Vero plate for
two hours after which VSV was added. (ii) PDE was initially
incubated at room temperature and at 37°C with VSV for two
hours, after which the combination was added to the Vero
plate. (iii) VSV was incubated onto a Vero plate for two hours
after which the PDE was added. For each experiment media
was used as control. Inhibition of CPE was recorded as
previously detailed.
In a further experiment three samples of PDE-I were exam-
ined for their AVA on Vero plates with VSV (dilution —3) under
the following conditions: (i) PDE incubated onto Vero plate for
two hours after which VSV was added, these PDE-I samples
were designated as PDE control; (ii) PDE control in which the
pH of the media was reduced to 2; (iii) PDE-I samples incubated
following freezing and thawing procedures (iv) PDE-I incubated
Table 1. Inhibitory effect of PDE-I samples in virus dilutions —3,
—4, —5 versus virus control, as reflected by the scoring system in the
text
Control PDE
Tissue
Virus —4 —5 control
dilution a b a b a b a b
Mean 1.92 0.32 2.15 0.52 2.61 1.21 2.89 2.68
SD 0.81 0.28 0.98 0.48 0.70 0.90 0.89 0.79
P <0.01 <0.01 <0.01 NS
Results are expressed as mean + SD. NS is non-significant.
P < 0.01 between tissue control and PDE in dilutions —3, —4, —5. a,
control; b, PDE.
after heating the samples to 52°C and 65°C, respectively, for 30
minutes. VSV on Vero was used as virus control. Inhibition of
CPE was recorded as previously detailed.
Anti-viral antibody determinations
To test the possibility that the anti-viral effect of PDE may be
mediated by specific anti-viral antibodies, all PDE samples
were examined for the presence of such antibodies. Antibodies
to HSV were assayed by the microneutralization test (NT) [25]
and ELISA, VSV by ELISA [26], Cox B by the enterovirus
complement fixation test (Behring Institute) [271 and by NT
using standard anti Cox B serum, and CMV by complement
fixation and ELISA [28, 29].
Results
Virus isolation
All 129 PDE samples tested did not demonstrate any CPE
(indicative of the presence of virus). Of the 18 PDE samples
obtained under conditions considered as clinical peritonitis, 14
showed bacterial growth by conventionally used culture tech-
niques. PDE cell count in cases of peritonitis was always >500
cells/pm (range 500 to 10.000, mean 1666) versus <175 (range 4
to 174, mean 59) with no peritonitis (P < 0.01). As stated, none
of these 14 or the 4 culture-negative PDE samples yielded any
virus growth.
Anti-viral activity of PDE
With human and monkey tissue cultures PDE-I exhibited
inhibition of CPE of the various viruses tested (Fig. 1). Using
the scoring system a statistically significant difference was
shown between the inhibitory effect of PDE-I samples in virus
dilutions —3, —4, —5 versus virus control, whereas no differ-
ence was demonstrated between PDE control and virus control
(Table 1). No such inhibition was seen with L-929, the mouse
cell culture. PDE-C samples, in the dilute form, showed only
weak or absent inhibition of CPE. Following lyophilization,
these same PDE-C samples were found to inhibit CPE to a
degree similar to the PDE-I samples. No inhibition of CPE was
evident with any of the control solutions (Fig. 2).
The inhibition of CPE (as measured by Para-3 on Vero) was
20.9 + 28.6% versus virus control (P <0.01).
Virus dilution
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Virus dilution (—4)
PDE (2 hr) + VSV
Media (2 hr) + VSV
PDE + VSV (2 hr)
Media + VSV (2 hr)
VSV (2 hr) + PDE
VSV (2 hr) + Media
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Fig. 2. Tissue culture p/ate (VSV on Vero) showing lack of inhibition
of CPE of various solutions in comparison to the inhibitory effect of
CPE by PDE.
Table 2. Minimal inhibitory concentrations (MIC) of different
peritoneal dialysis effluents from patients on intermittent peritoneal
dialysis (PDE-I)
PDE —1
HSV
(1—4) VSV (—5)
Cox B
(—3)
1 1/16 1/16 1/16
2 1/64 1/64 1/16
3 1/16 1/16 1/16
4 1/64 1/16 1/16
5 1/64 1/16 1/16
MIC renged from 1/16 (PDE diluted x4) to 1/64 (PDE diluted x6).
Minimal inhibitory concentration of PDE
Results of the MIC of five different PDE-I samples are shown
in Table 2. MIC ranged from 1/16 to 1/64. The CPE of HSV was
inhibited to 1/64 by three out of the five PDE samples examined,
VSV was to 1/64 by only one out of five and Cox B to 1/16 only
by five of the five samples tested.
Anti-viral activity of PDE versus standard IFN
Following the 24 hour incubation of PDE onto FS- 11 and
human Wish amniotic cells, inhibition of CPE of VSV was
obtained. This inhibitory effect was, however, abolished when
the TC were rinsed free of PDE prior to the addition of VSV.
Standard IFN and produced an inhibition of CPE which per-
sisted after rinsing the plates.
Assays for human IFN
No human IFN a, /3 or y was detected in any of the PDE
examined.
Characterization of anti-viral activity
Results of the first experiment (varying incubation se-
quences) are detailed in Figure 3. As can be seen, PDE inhibited
CPE whether incubated first onto the culture plate, when
incubated together with VSV onto the culture plate at room
temperature and at 37°C or when added two hours after VSV
was inoculated onto the culture plate. In all procedures media
control did not show any inhibition of CPE.
Fig. 3. Tissue culture p/ate (VSV in dilution —4 on Vero) showing the
effect of different experimental procedures (as outlined) on the inhibi-
tion of CPE. PDE inhibited CPE (shaded wells) under all conditions.
In the second experiment inhibition of CPE was maintained
despite reduction of media pH to 2, freezing and thawing
procedures and heating to 52°C. It was, however, abolished by
heating to 65°C.
Anti-viral antibodies
Antibody titers were found to be positive only for HSV, as
assayed by both the NT and ELISA methods. Antibody titers of
PDE-I were similar to those of PDE-C (before lyophilization)
despite the difference in the degree of inhibition of CPE.
Discussion
Peritoneal dialysis (PD) and in particular CAPD, has become
an increasingly used modality of treatment for patients with
end-stage renal disease [1, 3]. As yet, one of the major compli-
cations of PD is peritonitis [2—61. The literature abounds with
reviews documenting bacterial (70 to 90% of episodes) and
fungal (up to 10%) peritonitis [2, 4, 6—8]. Aseptic or culture-
negative peritonitis accounts for up to 20% of episodes [6].
However, except for an isolated case report recently published
[9], viral peritonitis has hitherto not been reported. This is
rather striking in view of the fact that these patients are prone
to opportunistic and viral infections [12]. It is possible that the
group of culture negative peritonitis contains within it undetec-
ted viral etiology, not picked up by conventional culture meth-
ods. In order to exclude this possibility multiple PDE from both
infected and uninfected patients were inoculated onto Vero and
FS- 11 tissue cultures in an attempt to isolate the commonly
infective viruses belonging to the herpes and enteroviruses
groups. No viral growth was demonstrated. We therefore
postulated that PDE itself may have an inherent anti-viral
effect.
PDE was examined for AVA in a manner analogous to testing
the AVA of IFN [17], apart from the fact that the virus was
added onto the TC immediately after the addition of PDE. The
inhibition of the CPE of the challenge virus was taken as a
measure of the AVA. Using various TC and viruses, PDE
consistently inhibited the viral CPE. The inhibition of CPE was
seen regardless of the presence of peritonitis with no correlation
between the inhibition of CPE and the PDE cell count. Inhibi-
Virus dilution Virus dilution (- 4)
—3 —4 —5 —6
Media
Dextrose
PDE
Dianeal (1.5%)
Dianeal (4.25%)
Ned
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tion of CPE was not demonstrated with the control solutions.
Both DNA (HSV and CMV) and RNA (VSV, Cox B, and
Para-3) viruses were inhibited. The inhibition was present in
human and monkey tissue cultures and absent in a mouse
culture. This suggests that the AVF may be, in part, species
specific. PDE-I showed a more intense AVA. However, after
lyophilization, PDE-C showed a similar degree of AVA. Anti-
viral activity is therefore probably related to the concentration
of AVF in PDE. The MIC of the AVF differed amongst the
various viruses tested, but was never less than 1/16.
Among the naturally occurring anti-viral agents in man are
IFN [13, 141 and specific anti-viral antibodies. IFN are in
general species specific, that is, they are only active in cells of
the same species as that in which they are produced. IFN
induces an antiviral state which, however, takes time to de-
velop and is dependent on RNA and protein synthesis [14].
When tested in vitro, after 24 hours of incubation, standard IFN
produces an inhibition of CPE which is maintained even when
the culture plates are rinsed free of IFN prior to the addition of
virus. This is in contrast to the AVA of PDE which was
abolished by rinsing the plates (Vero and FS-l 1) before the
addition of virus (VSV). Thus, in this respect, the AVF behaves
unlike standard IFN. Prior to setting out to determine whether
PDE has any AVA, we addressed this issue in the plasma of
seven of our intermittent PD patient population. No inhibition
of CPE was observed with these uremic plasma test samples
(unpublished observation). The inhibition of CPE by PDE was
also seen to occur independent of the sequence of incubation.
The demonstration of AVA occurring even after viral entry into
the host cell has been accomplished (a process which usually
takes 10 to 15 minutes) differentiates the AVF of PDE from that
of IFN. Further characterization of the AVF showed it to be
resistant to a pH of 2, freezing and thawing and heating to 52°C.
Its action was, however, abolished by heat inactivation to 65°C.
This fact is against the AVF being an endotoxin (liposaccharide)
which requires heating to 130°C for a full hour before inactiva-
tion. Finally, no human IFN a was detected by a bioassay using
MDBK cells nor were human IFN /3 and y detected by a RIA
using specific anti IFN /3, y monoclonal antibodies. Our con-
tention is that the AVF is not a known human IFN and probably
not an endotoxin.
The other naturally occurring anti-viral agents in man that we
sought to exclude as the AVF were specific anti-viral antibod-
ies. No antibodies against VSV, CMV and CoxB were detected.
The only antibodies found were those against VSV, but their
titer did not correlate with the MIC of the AVF. It appears,
therefore, that the AVA of PDE against HSV was not mediated
by these specific anti-HSV antibodies. A further argument
against antiviral antibodies being the AVF is the fact that AVA
was demonstrated when PDE was added two hours following
the addition of virus, as antibodies can only exert their effect
extracellularly.
In conclusion, PDE seems to possess an inherent anti-viral
activity. The proposed AVF exhibits partial species specificity
and is active against human and animal viruses, both DNA and
RNA. Using the methods outlined above, the AVF does not
appear to be a known human IFN (a, /3 or y) and does not
behave in a manner characteristic of standard IFN. It is not
related to anti-viral antibodies or endotoxin. Further investiga-
tions are needed in order to delineate the AVF and elucidate its
mechanism of action.
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